Genetic variations in thymidine phosphorylase could impact the effectiveness of tipiracil hydrochloride by influencing how well the drug inhibits this enzyme, which is critical for preventing the degradation of trifluridine. This variation affects the amount of trifluridine that can be incorporated into DNA, subsequently influencing the efficacy of treatments for conditions like metastatic colorectal cancer.